387 related articles for article (PubMed ID: 28842263)
1. Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.
Hayashi T; Jean M; Huang H; Simpson S; Santoso NG; Zhu J
Antiviral Res; 2017 Oct; 146():76-85. PubMed ID: 28842263
[TBL] [Abstract][Full Text] [Related]
2. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
[TBL] [Abstract][Full Text] [Related]
3. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.
Stoszko M; De Crignis E; Rokx C; Khalid MM; Lungu C; Palstra RJ; Kan TW; Boucher C; Verbon A; Dykhuizen EC; Mahmoudi T
EBioMedicine; 2016 Jan; 3():108-121. PubMed ID: 26870822
[TBL] [Abstract][Full Text] [Related]
4. RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency.
Méndez C; Ledger S; Petoumenos K; Ahlenstiel C; Kelleher AD
Retrovirology; 2018 Oct; 15(1):67. PubMed ID: 30286764
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cells are attracted to latent HIV-1-infected cells and enable virus reactivation via a non-canonical PI3K-NFκB signaling pathway.
Chandra PK; Gerlach SL; Wu C; Khurana N; Swientoniewski LT; Abdel-Mageed AB; Li J; Braun SE; Mondal D
Sci Rep; 2018 Oct; 8(1):14702. PubMed ID: 30279437
[TBL] [Abstract][Full Text] [Related]
6. Block-And-Lock: New Horizons for a Cure for HIV-1.
Moranguinho I; Valente ST
Viruses; 2020 Dec; 12(12):. PubMed ID: 33334019
[TBL] [Abstract][Full Text] [Related]
7. Finding a cure for HIV: will it ever be achievable?
Lewin SR; Evans VA; Elliott JH; Spire B; Chomont N
J Int AIDS Soc; 2011 Jan; 14():4. PubMed ID: 21255462
[TBL] [Abstract][Full Text] [Related]
8. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
9. Procyanidin trimer C1 derived from Theobroma cacao reactivates latent human immunodeficiency virus type 1 provirus.
Hori T; Barnor J; Nguyen Huu T; Morinaga O; Hamano A; Ndzinu J; Frimpong A; Minta-Asare K; Amoa-Bosompem M; Brandful J; Odoom J; Bonney J; Tuffour I; Owusu BA; Ofosuhene M; Atchoglo P; Sakyiamah M; Adegle R; Appiah-Opong R; Ampofo W; Koram K; Nyarko A; Okine L; Edoh D; Appiah A; Uto T; Yoshinaka Y; Uota S; Shoyama Y; Yamaoka S
Biochem Biophys Res Commun; 2015 Apr; 459(2):288-293. PubMed ID: 25727021
[TBL] [Abstract][Full Text] [Related]
10. Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency.
Kyei GB; Meng S; Ramani R; Niu A; Lagisetti C; Webb TR; Ratner L
mBio; 2018 Nov; 9(6):. PubMed ID: 30401776
[TBL] [Abstract][Full Text] [Related]
11. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.
Quivy V; De Walque S; Van Lint C
Subcell Biochem; 2007; 41():371-96. PubMed ID: 17484137
[TBL] [Abstract][Full Text] [Related]
12. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.
Rasmussen TA; Tolstrup M; Winckelmann A; Østergaard L; Søgaard OS
Hum Vaccin Immunother; 2013 Apr; 9(4):790-9. PubMed ID: 23563519
[TBL] [Abstract][Full Text] [Related]
13. A broad drug arsenal to attack a strenuous latent HIV reservoir.
Stoszko M; Ne E; Abner E; Mahmoudi T
Curr Opin Virol; 2019 Oct; 38():37-53. PubMed ID: 31323521
[TBL] [Abstract][Full Text] [Related]
14. HIV Provirus Stably Reproduces Parental Latent and Induced Transcription Phenotypes Regardless of the Chromosomal Integration Site.
Hashemi FB; Barreto K; Bernhard W; Hashemi P; Lomness A; Sadowski I
J Virol; 2016 Jun; 90(11):5302-14. PubMed ID: 26984732
[TBL] [Abstract][Full Text] [Related]
15. Heme arginate potentiates latent HIV-1 reactivation while inhibiting the acute infection.
Shankaran P; Vlkova L; Liskova J; Melkova Z
Antiviral Res; 2011 Dec; 92(3):434-46. PubMed ID: 22001321
[TBL] [Abstract][Full Text] [Related]
16. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
17. HIV latency reversing agents act through Tat post translational modifications.
Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ
Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762
[TBL] [Abstract][Full Text] [Related]
18. Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products.
Richard K; Williams DE; de Silva ED; Brockman MA; Brumme ZL; Andersen RJ; Tietjen I
Viruses; 2018 Jun; 10(7):. PubMed ID: 29954099
[TBL] [Abstract][Full Text] [Related]
19. PIWIL4 Maintains HIV-1 Latency by Enforcing Epigenetically Suppressive Modifications on the 5' Long Terminal Repeat.
He Z; Jing S; Yang T; Chen J; Huang F; Zhang W; Peng Z; Liu B; Ma X; Wu L; Pan T; Zhang X; Li L; Cai W; Tang X; Zhang J; Zhang H
J Virol; 2020 May; 94(10):. PubMed ID: 32161174
[TBL] [Abstract][Full Text] [Related]
20. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus.
Yang W; Sun Z; Hua C; Wang Q; Xu W; Deng Q; Pan Y; Lu L; Jiang S
Microbes Infect; 2018; 20(9-10):626-634. PubMed ID: 29126877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
